The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study
|Journal||Volume 85 - 2022|
|Issue||Fasc.3 - Original articles|
|Author(s)||J. De Graeve 1, E. Vanderstraeten 1, T. Delvaeye 1, S. De Lepeleere 1, T. De Somer 1, C. Van Steenkiste 1 2|
VIEW FREE PDF
(1) Gastroenterology & Hepatology, AZ Maria Middelares, Gent, Belgium
(2) Gastroenterology, UZ Antwerpen, Edegem, Belgium
Background and study aims: Advanced liver disease frequently culminates in hepatic encephalopathy (HE), which can be classified as covert or overt HE, with subtle or clinically obvious changes respectively. 30-40% of patients with cirrhosis develop overt HE, which negatively affects the patients’ quality of life. Next to lactulose, rifaximin-a has been prescribed as a second line therapy to treat and reduce the risk of recurrence of overt HE. In this study, we aimed to evaluate the effect of rifaximin-a therapy, both on the number of occurring infections and on the evolution in hospital admissions of patients with overt HE.
Patients and methods: A total of 66 cirrhotic patients, treated for at least 6 months with rifaximin-a at AZ Maria Middelares, between October 1st 2014 and January 1st 2020, were included in the study analysis. Medical records of all patients were evaluated over a period of 6 months prior and after initiation of rifaximin-a therapy.
Results: Data analysis revealed that the included cirrhotic patients were severely ill, with a mean model for end-stage liver disease (MELD) score of 21, and a median Child Pugh score of 11. Among these patients, rifaximin-a treatment significantly downgraded the total number of infections, with a main effect on respiratory infections. Furthermore, rifaximin-a therapy led to a significant decrease in HE-related, as well as in other liver-related hospital admissions.
Conclusions: This study confirms the potential value of rifaximin-a in reducing the number of developing infections and hospital admissions in a severely ill cirrhotic patient population.
Keywords: end-stage liver disease, rifaximin-a, intensive care, healthcare utilization.
© Acta Gastro-Enterologica Belgica.